natgillin/translations-raw huggingface dataset:
An immunoconjugate comprising an antibody according to any one of claims to 1 to 19 conjugated or linked to at least one growth inhibitory agent. 
Imunokonjugat naznačen time da sadrži protutijelo prema bilo kojem od zahtjeva 1 do 19 konjugirano ili vezano na najmanje jedno sredstvo za inhibiciju rasta.
An immunoconjugate according to claim 22, wherein said growth inhibitory agent is a cytotoxic agent or a radioactive isotope. 
Imunokonjugat prema zahtjevu 22, naznačen time da je navedeno sredstvo za inhibiciju rasta citotoksično sredstvo ili radioaktivni izotop.
An immunoconjugate according to claim 22 or 23, wherein said growth inhibitory agent is selected from the group consisting of chemotherapeutic agents, enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins, taxoids, vincas, taxanes, maytansinoid or maytansinoid analogs, tomaymycin or pyrrolobenzodiazepine derivatives, cryptophycin derivatives, leptomycin derivatives, auristatin or dolastatin analogs, prodrugs, topoisomerase II inhibitors, DNA alkylating agenst, anti-tubulin agents, and CC-1065 or CC-1065 analogs. 
Imunokonjugat prema zahtjevu 22 ili 23, naznačen time da je navedeno sredstvo za inhibiciju rasta odabrano iz skupine koju čine kemoterapeutska sredstva, enzimi, antibiotici, i toksini kao što su toksini malih molekula ili enzimatski aktivni toksini, taksoidi, vinka, taksani, majtanzinoid ili analozi majtanzinoida, tomamicin ili derivate pirolobenzodiazepina, derivate kriptoficina, derivate leptomicina, analoge auristatina ili dolastatina. predlijekove, inhibitore topoizomeraze II, DNA alkilirajuća sredstva, anti-tubulinska sredstva, te analoge CC-1065 ili CC-1065.
An immunoconjugate according to any one of claims 22 to 28, wherein the antibody comprises a heavy chain consisting of sequence SEQ ID NO:87 or a sequence at least 85% identical thereto and a light chain consisting of sequence SEQ ID NO:88 or a sequence at least 85% identical thereto. 
Imunokonjugat prema bilo kojem od zahtjeva 22 do 28, naznačen time da protutijelo sadrži teški lanac koji sadrži sekvencu SEQ ID NO:87 ili sekvencu koja je s njom barem 85% identična i laki lanac koji sadrži sekvencu SEQ ID NO:88 ili sekvencu koja je s njom barem 85% identična.
The antibody, immunoconjugate or pharmaceutical composition for the use according to claim 34 or 35, wherein the cancer is colorectal, stomach, lung, uterus cervix, pancreas, oesophagus, ovary, thyroid, bladder, endometrium, breast, liver, prostate, or skin cancer. 
Protutijelo, imunokonjugat ili farmaceutski pripravak za uporabu prema zahtjevu 32 ili 33, naznačeno time da rak je rak debelog crijeva, želuca, pluća, vrata maternice, gušterače, jednjaka, jajnika, štitnjače, mokraćnog mjehura, endometrija, dojke, jetre, prostate, ili rak kože.
An antibody for the use according to claim 37 or 38, wherein said use is for diagnosing the presence of a cancer in a subject, determining susceptibility of a patient having cancer to a therapeutic agent targeting CEACAM5, or monitoring effectiveness of anti-CEACAM5 cancer therapy or detecting cancer relapse after anti-CEACAM5 cancer therapy. 
Protutijelo za uporabu prema zahtjevu 35 ili 36, naznačen time da navedena uporaba je za dijagnosticiranje prisutnosti raka kod subjekta, određivanje osjetljivosti pacijenta koji ima rak na terapeutsko sredstvo koje cilja CEACAM5, ili praćenje učinkovitosti anti-CEACAM5 terapije raka ili otkrivanje povratka raka nakon anti-CEACAM5 terapije raka.
a filler which is a mixture of mannitol and dibasic calcium phosphate dihydrate; 
punilo koje je smjesa manitola i dvobaznog kalcijevog fosfata dihidrata;
a binder which is hydroxypropyl cellulose; 
vezivo koje je hidroksipropil celuloza;
a disintegrant which is sodium starch glycollate; and one or more lubricants. 
sredstvo za raspadanje koje je natrijev škrobni glikolat; i jedno ili više sredstava za podmazivanje.
mannitol in an amount of 20 to 45% by weight; 
manitol u količini od 20 do 45% težinski;
dibasic calcium phosphate dihydrate in an amount of 10 to 30% by weight; 
dvobazni kalcijev fosfat dihidrat u količini od 10 do 30% težinski;
hydroxypropylcellulose in an amount of 3 to 6% by weight; 
hidroksipropilcelulozu u količini od 3 do 6% težinski;
sodium starch glycolate in an amount of 2 to 6% by weight; and one or more lubricants in an amount of 0.5 to 3% by weight. 
natrijev škrobni glikolat u količini od 2 do 6% težinski; i jedno ili više sredstava za podmazivanje u količini od 0.5 do 3% težinski.
A pharmaceutical composition as defined in claim 1 or 2 wherein the lubricant is magnesium stearate. 
Farmaceutski pripravak kako je definirano u zahtjevu 1 ili 2 naznačen time da sredstvo za podmazivanje je magnezijev stearat.
The compound or a pharmaceutically acceptable salt thereof for use according to claim 17, wherein said Aβ-related pathology is Down's syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration. 
Spoj ili njegova farmaceutski prihvatljiva sol u skladu sa zahtjevom 1 naznačen time da je za uporabu u postupku liječenja ili prevencije Aβ-povezane patologije, pri čemu navedena Aβ-povezana patologija je Downov sindrom, β-amiloidna angiopatija, cerebralna amiloidna angiopatija, nasljedno cerebralno krvarenje, poremećaj povezan s kognitivnim poremećajem, MCI ("blagi kognitivni poremećaj"), Alzheimerova bolest, gubitak pamćenja, simptomi poremećaja pažnje povezani s Alzheimerovom bolesti, neurodegeneracija povezana s Alzheimerovom bolesti, demencija miješanog vaskularnog podrijetla, demencija degenerativnog porijekla, presenilna demencija, senilna demencija, demencija povezana s Parkinsonovom bolesti, progresivna supranuklearna paraliza i kortikobazalna degeneracija.
An isolated antibody which competes for binding to A3-B3 domain of human and Macaca fascicularis CEACAM5 proteins with an antibody comprising the variable heavy and light chains of an antibody selected from the group consisting of 
Izolirano protutijelo prema zahtjevu 1 koje se natječe u pogledu vezanja na A3-B3 domenu ljudskih i Macaca fascicularis CEACAM5 proteina s protutijelom koje sadrži varijabilne teške i lake lance od protutijela odabranog iz skupine koju čine
The immunoconjugate according to claim 7 or 8, wherein said growth inhibitory agent is selected from the group consisting of chemotherapeutic agents, enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins, taxoids, vincas, taxanes, maytansinoid or maytansinoid analogs, tomaymycin or pyrrolobenzodiazepine derivatives, cryptophycin derivatives, leptomycin derivatives, auristatin or dolastatin analogs, prodrugs, topoisomerase II inhibitors, DNA alkylating agenst, anti-tubulin agents, and CC-1065 or CC-1065 analogs. 
Imunokonjugat prema zahtjevu 22 ili 23, naznačen time da je navedeno sredstvo za inhibiciju rasta odabrano iz skupine koju čine kemoterapeutska sredstva, enzimi, antibiotici, i toksini kao što su toksini malih molekula ili enzimatski aktivni toksini, taksoidi, vinka, taksani, majtanzinoid ili analozi majtanzinoida, tomamicin ili derivate pirolobenzodiazepina, derivate kriptoficina, derivate leptomicina, analoge auristatina ili dolastatina. predlijekove, inhibitore topoizomeraze II, DNA alkilirajuća sredstva, anti-tubulinska sredstva, te analoge CC-1065 ili CC-1065.
the sum of these three constituents being equal to 100%, and wherein the microorganism belongs to the species Trichoderma reesei which is deleted for catabolic repression by glucose, 
te je zbroj navedenih sastojaka jednak 100%, i mikroorganizam pripada vrsti Trichoderma reesei i briše se radi katabolitičke represije s glukozom.
The process of claim 1, wherein the carbon source in (a) is glucose, xylose, lactose, residues obtained after ethanolic fermentation of monomeric sugars of the enzymatic hydrolysates of cellulosic biomass and/or an unrefined extract of hydrosoluble pentoses derived from pre-treatment of a cellulosic biomass. 
Postupak prema jednom od prethodnih zahtjeva, naznačen time da je karbonatni supstrat koji se koristi tijekom faze rasta odabran od glukoze, ksiloze, laktoze, ostataka dobivenih nakon etanolne fermentacije monomernih šećera enzimatskog hidrolizata celulozne biomase i/ili nerafinirani ekstrakt vodotopivih pentoza koje je moguće dobiti iz pred-obrade celulozne biomase.
The method according to claim 6 or 7, wherein said allergen is selected from the group consisting of a tree pollen allergens, grass pollen allergens, herb pollen allergens, weed pollen allergens, mite allergens, venom allergens, animal hair and dandruff allergens and food allergens. 
Postupak prema zahtjevu 6 ili 7, naznačen time da je navedeni alergen odabran iz skupine koju čine alergeni peludi drveća, alergeni peludi trave, alergeni peludi biljaka, alergeni peludi korova, alergeni grinja, alergeni otrova, alergeni životinjskih dlaka i peruti i alergeni hrane.
The system (10) according to claim 1, wherein said fish loading area (18) and/or said fish unloading area (58) comprises a conveyer assembly, such as e.g. a conveyer belt. 
Sustav (10) prema zahtjevu 1, naznačen time, da navedeno područje punjenja ribom (18) i/ili navedeno područje izbacivanja ribe (58), obuhvaća transportni sklop, kao što je primjerice transportna traka.
The system (10) according to any of the previous claims, wherein said separation arrangement (42) is fixed onto said grabbing unit (38). 
Sustav (10) prema bilo kojem od prethodnih zahtjeva, naznačen time, da je navedeni separacijski uređaj (42) učvršćen na navedenu zahvatnu jedinicu (38).
The system (10) according to any of the previous claims, further including a packing station, said packing station providing a multitude of containers for receiving said fish, said multitude of containers are designated different size ranges, said fish (22) is packed in the corresponding container according to the size of said fish, which is derived from said digital representation. 
Sustav (10) prema bilo kojem od prethodnih zahtjeva, naznačen time, da on nadalje obuhvaća položaj za pakiranje, pri čemu je taj položaj za pakiranje opremljen s mnoštvom spremnika za prihvat navedene ribe (22), dok je to mnoštvo spremnika naznačeno prema različitim rasponima veličina, gdje se navedena riba (22) pakira u odgovarajući spremnik prema dimenzijama navedene ribe, koje proizlaze iz spomenutog digitalnog prikazivanja.
and Z6 are either taken together to form an oxo group at the carbon atom to which they are attached; or Z5 and Z6 are each independently selected from the group consisting of H, -C1-6alkyl, -OT1 and -N(T2)(T3); 
i Z6 ili su uzeti zajedno kako bi formirali okso skupinu na ugljikovom atomu na koji su vezani; ili Z5 i Z6 su svaki neovisno odabrani iz skupine koju čine H, -C1-6alkil, -OT1 i -N(T2)(T3);
A compound according to claim 1, wherein X1 is selected from the group consisting of H, F, Cl, Br, I, -OT1, -N(T2)(T3), -NHC(=O)T4, nitro, cyano, cyclopropyl and -C1-3alkyl; and X2 and X3 are independently selected from the group consisting of F, Cl, Br and I. 
Spoj prema zahtjevu 1, pri čemu X1 je odabran iz skupine koju čine H, F, Cl, Br, I, -OT1, -N(T2)(T3), -NHC(=O)T4, nitro, cijano, ciklopropil i -C1-3alkil; i X2 i X3 su neovisno odabrani iz skupine koju čine F, Cl, Br i I.
A compound according to any one of the preceding claims, wherein the pharmaceutically acceptable salt is selected from the group consisting of the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate and pamoate. 
Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time da je farmaceutski prihvatljiva sol odabrana iz skupine koju čine hidroklorid, hidrobromid, hidrojodid, nitrat, sulfat, bisulfat, fosfat, kiseli fosfat, izonikotinat, acetat, laktat, salicilat, citrat, tartrat, pantotenat, bitartrat, askorbat, sukcinat, maleat, gentisinat, fumarat, glukonat, glukaronat, saharat, format, benzoat, glutamat, metansulfonat, etansulfonat, benzensulfonat, p-toluensulfonat i pamoat.
A pharmaceutical composition according to claim 9, wherein said composition comprises said compound as the only pharmaceutically active agent or wherein said composition comprises at least one further independent pharmaceutically active agent. 
Farmaceutski pripravak prema zahtjevu 9, naznačen time da navedeni pripravak sadrži navedeni spoj kao jedino farmaceutski aktivno sredstvo ili pri čemu navedeni pripravak sadrži barem još jedno neovisno farmaceutski aktivno sredstvo.
alternatively reacting the compound of formula (XI) with a compound of formula (VI) wherein LG1 is a first leaving group and LG2 is a second leaving group; in the presence of a base; in a mixture of water and an organic solvent; 
alternativno reakciju spoja s formulom (XI) sa spojem s formulom (VI) pri čemu LG1 je prva izlazna skupina i LG2 je druga izlazna skupina; u prisutnosti baze; u smjesi vode i organskog otapala;
alternatively, reacting the compound of formula (XI-S) with a compound of formula (VI-S), wherein LG1 is a first leaving group and LG2 is a second leaving group; in the presence of a base; in a mixture of water and an organic solvent; 
alternativno, reakciju spoja s formulom (XI-S) sa spojem s formulom (VI-S), pri čemu LG1 je prva izlazna skupina i LG2 je druga izlazna skupina; u prisutnosti baze; u smjesi vode i organskog otapala;
A process as in Claim 2, wherein the compound of formula (V-S) is reacted with the compound of formula (VIII-S) in an organic solvent and wherein the organic solvent is toluene. 
Postupak prema zahtjevu 2, naznačen time da spoj s formulom (V-S) reagira sa spojem s formulom (VIII-S) u organskom otapalu i pri čemu organsko otapalo je toluen.
A process as in Claim 2, wherein the compound of formula (V-S) is reacted with the compound of formula (VIII-S) at a temperature of reflux temperature. 
Postupak prema zahtjevu 2, naznačen time da spoj s formulom (V-S) reagira sa spojem s formulom (VIII-S) na temperaturi refluksa.
A process as in Claim 2, wherein the compound of formula (IX-S) is reacted with the reducing agent in the presence of an acid. 
Postupak prema zahtjevu 2, naznačen time da spoj s formulom (IX-S) reagira sa sredstvom za redukciju u prisutnosti kiseline.
A process as in Claim 2, wherein the reducing agent is added as a solution in water, stabilized with sodium hydroxide in an amount of 0.1 molar equivalents. 
Postupak prema zahtjevu 2, naznačen time da se sredstvo za redukciju dodaje kao otopina u vodi, stabilizirana natrijevim hidroksidom u količini od 0.1 molarnih ekvivalenata.
A process as in Claim 2, wherein the reducing agent is sodium borohydride. 
Postupak prema zahtjevu 2, naznačen time da sredstvo za redukciju je natrijev borohidrid.
A process as in Claim 8, wherein the sodium borohydride is present in an amount in the range of from 0.5 to 1.5 molar equivalents. 
Postupak prema zahtjevu 8, naznačen time da je natrijev borohidrid prisutan u količini u rasponu od 0.5 do 1.5 molarnih ekvivalenata.
A process as in Claim 2, wherein the compound of formula (XI-S) is reacted with the compound of formula (VI-S) in an organic solvent selected from the group consisting of methyl t-butyl ether, toluene and 2-methyl-THF. 
Postupak prema zahtjevu 2, naznačen time da spoj s formulom (XI-S) reagira sa spojem s formulom (VI-S) u organskom otapalu odabranom iz skupine koja sadrži metil t-butil eter, toluen i 2-metil-THF.
A process as in Claim 2, wherein the compound of formula (XI-S) is reacted with the compound of formula (VI-S) at a temperature in the range of from 0°C to 35°C. 
Postupak prema zahtjevu 2, naznačen time da spoj s formulom (XI-S) reagira sa spojem s formulom (VI-S) na temperaturi u rasponu od 0°C do 35°C.
A process as in Claim 2, wherein the compound of formula (VI-S) in MTBE is reacted with the compound of formula (XI-S) in water, in the presence of 30% NaOH, at a temperature in the range of from 10°C to 15°C. 
Postupak prema zahtjevu 2, naznačen time da spoj s formulom (VI-S) u MTBE reagira sa spojem s formulom (XI-S) u vodi, u prisutnosti 30% NaOH, na temperaturi u rasponu od 10°C do 15°C.
A process as in Claim 18, wherein the potassium hydroxide is present in an amount in the range of from 2.0 to 4.0 molar equivalents. 
Postupak prema zahtjevu 18, naznačen time da je kalijev hidroksid prisutan u količini u rasponu od 2.0 do 4.0 molarnih ekvivalenata.
A process as in Claim 2, wherein the compound of formula (X-S) is reacted with the compound of formula (XII-A) in an organic solvent selected from the group consisting of toluene, acetonitrile and a mixture of toluene and water. 
Postupak prema zahtjevu 2, naznačen time da spoj s formulom (X-S) reagira sa spojem s formulom (XII-A) u organskom otapalu odabranom iz skupine koja sadrži toluen, acetonitril i smjesa toluena i vode.
A process as in Claim 2, wherein the compound of formula (X-S) is reacted with the compound of formula (XII-C) at reflux temperature. 
Postupak prema zahtjevu 2, naznačen time da spoj s formulom (X-S) reagira sa spojem s formulom (XII-C) na temperaturi refluksa.
A process as in Claim 2, wherein LG2 is chloro and wherein the compound of formula (X-S) is prepared as its corresponding HCl salt. 
Postupak prema zahtjevu 2, naznačen time da LG2 je klor i pri čemu je spoj s formulom (X-S) pripremljen kao njegova odgovarajuća HCl sol.
A process as in Claim 22, wherein the compound of formula (X-S) as its corresponding HCl salt is reacted with a first inorganic base prior to reacting with compound of formula (XII-C). 
Postupak prema zahtjevu 22, naznačen time da spoj s formulom (X-S) kao njegova odgovarajuća HCl sol reagira s prvom anorganskom bazom prije reakcije sa spojem formule (XII-C).
A process as in Claim 24, wherein the sodium carbonate is present in an amount sufficient to liberate the compound of formula (X-S) as a free base. 
Postupak prema zahtjevu 24, naznačen time da je natrijev karbonat prisutan u količini dovoljnoj da oslobodi spoj s formulom (X-S) kao slobodnu bazu.
A process as in Claim 24, wherein the sodium carbonate is present in an amount of 1.5 molar equivalents. 
Postupak prema zahtjevu 24, naznačen time da je natrijev karbonat prisutan u količini od 1.5 molarnih ekvivalenata.
alternatively reacting the compound of formula (XI-S) with a compound of formula (VI-S), wherein LG2 is a second leaving group; in the presence of a base; in a mixture of water and an organic solvent; 
alternativno reakciju spoja s formulom (XI-S) sa spojem s formulom (VI-S), pri čemu LG2 je druga izlazna skupina; u prisutnosti baze; u smjesti i organskog otapala;
to yield the corresponding compound of formula (X-S). 
da se dobije odgovarajući spoj s formulom (X-S).
A process as in Claim 27, wherein the compound of formula (V-S) is reacted with the compound of formula (VIII-S) in toluene, at a temperature greater than 40°C. 
Postupak prema zahtjevu 27, naznačen time da spoj s formulom (V-S) reagira sa spojem s formulom (VIII-S) u toluenu, na temperaturi većoj od 40°C.
A process as in Claim 27, wherein the compound of formula (IX-S) is reacted with the reducing agent in the presence of an acid or a process as in Claim 6; wherein the acid is hydrochloric acid; and wherein the hydrochloric acid is present in an amount in the range of from 3.0 to 5.0 molar equivalents. 
Postupak prema zahtjevu 27, naznačen time da spoj s formulom (IX-S) reagira sa sredstvom za redukciju u prisutnosti kiseline ili postupak prema zahtjevu 6; pri čemu kiselina je klorovodična kiselina; i pri čemu je klorovodična kiselina prisutna u količini u rasponu od 3.0 do 5.0 molarnih ekvivalenata.
A process as in Claim 27, wherein the reducing agent is sodium borohydride and wherein the reducing agent is added as a solution in water, stabilized with 0.1 molar equivalents of sodium hydroxide. 
Postupak prema zahtjevu 27, naznačen time da sredstvo za redukciju je natrijev borohidrid i pri čemu se sredstvo za redukciju dodaje kao otopina u vodi, stabilizirana s 0.1 molarnih ekvivalenata natrijevog hidroksida.
A process as in Claim 27, wherein LG2 is chloro; wherein the compound of formula (VI-S) is present in an amount in the range of from 1.0 to 1.5 molar equivalents; and wherein the compound of formula (X-S) is prepared as its corresponding HCl salt. 
Postupak prema zahtjevu 27, pri čemu LG2 je klor; naznačen time da je spoj s formulom (VI-S) prisutan u količini u rasponu od 1.0 do 1.5 molarnih ekvivalenata; i pri čemu je spoj s formulom (X-S) pripremljen kao njegova odgovarajuća HCl sol.
A process as in Claim 27, wherein the compound of formula (XI-S) is reacted with the compound of formula (VI-S) in an organic solvent selected from the group consisting of toluene and 2-methyl-THF; and at a temperature in the range of form room temperature to 35°C. 
Postupak prema zahtjevu 27, naznačen time da spoj s formulom (XI-S) reagira sa spojem s formulom (VI-S) u organskom otapalu odabranom iz skupine koja sadrži toluen i 2-metil-THF; i na temperaturi u rasponu od sobne temperature do 35°C.
A process as in Claim 27, wherein the compound of formula (XI-S) in water is reacted with a compound of formula (VI-S) in MTBE, in the presence of a base; wherein the base is 30% NaOH; at a temperature in the range of from 10°C to 15°C. 
Postupak prema zahtjevu 27, naznačen time da spoj s formulom (XI-S) u vodi reagira sa spojem s formulom (VI-S) u MTBE, u prisutnosti baze; pri čemu je baza 30% NaOH; na temperaturi u rasponu od 10°C do 15°C.
A purified allergen extract which is obtainable by a method comprising a step of ultrafiltration of an aqueous allergen extract on a 1-10 kDa membrane with at least 5 volumes of an ammonium bicarbonate solution, and a step of sterile filtration on a 0.22 µm filter. 
Postupak za pripremanje pročišćenog ekstrakta alergena, naznačen time da postupak sadrži korak ultrafiltracije vodenog ekstrakta alergena na 1-10 kDa membrani s barem 5 volumena otopine amonijevog bikarbonata, te korak sterilne filtracije na 0.22 µm filteru.
A purified allergen extract according to claim 5 or 6, wherein said allergen is selected from the group consisting of a tree pollen allergens, grass pollen allergens, herb pollen allergens, weed pollen allergens, mite allergens, venom allergens, animal hair and dandruff allergens and food allergens. 
Postupak prema zahtjevu 6 ili 7, naznačen time da je navedeni alergen odabran iz skupine koju čine alergeni peludi drveća, alergeni peludi trave, alergeni peludi biljaka, alergeni peludi korova, alergeni grinja, alergeni otrova, alergeni životinjskih dlaka i peruti i alergeni hrane.
The concrete block according to claim 3, wherein said continuous holes (6) on the upper and bottom side of said base block (4) have a widening (8) for holding the thickening (7) of said stones. 
Betonski blok prema zahtjevu 3, naznačeno time da praznine u slijedu (6) na gornjoj i donjoj strani spomenutog baznog bloka (4) ima proširenje (8) za držanje zadebljanja (7) spomenutih jezgri.
The method according to claim 13, wherein said base block (4) is nearly immediately removed from the press after pressing. 
Metoda prema zahtjevu 13, naznačeno time da je spomenuti bazni blok (4) gotovo odmah maknut iż preše nakon prešanja.